cb 10375 has been researched along with Carcinoma 256, Walker in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abel, G; Goddard, PM; Harrap, KR; Judson, IR; Newell, DR; Rutty, CJ | 1 |
1 other study(ies) available for cb 10375 and Carcinoma 256, Walker
Article | Year |
---|---|
Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.
Topics: Altretamine; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Kinetics; Male; Mice; Mice, Inbred BALB C; Plasmacytoma; Rats; Rats, Inbred Strains; Solubility; Triazines | 1986 |